DL-Aminoglutethimide is a first generation, and a potent but nonselective aromatase inhibitor. Aminoglutethimide inhibits the enzymatic side-chain cleavage of cholesterol [
C0318] to pregnenolone [
P0786], mediated through the binding of aminoglutethimide to cytochrome P 450, resulting in a decrease in the production of adrenal glucocorticoids, mineralocorticoids, estrogens, and androgens. Besides, aminoglutethimide-P450 complexes block enzymatic 11- and 18-hydroxylation steps required for the aromatization of androgens to estrogens. Aminoglutethimide is used for the treatment of Cushing’s syndrome, breast and prostate cancer. (The product is for research purpose only.)